Is pemetinib available in China? How much does it cost?

Pemetinib, also known as pemetinib, is an oral anti-cancer drug that targets specific genetic mutations. As a potent and selective FGFR receptor tyrosine kinase inhibitor, it mainly targets FGFR1, FGFR2 and FGFR3 in the fibroblast growth factor receptor (FGFR) and prevents the growth and spread of tumor cells by inhibiting the activity of these receptors. The development of pemetinib provides new treatment opportunities for adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one prior systemic therapy and are confirmed to have FGFR2 fusions or rearrangements.

In clinical studies, pemetinib has shown significant efficacy, especially in inhibiting tumor growth and improving patient survival rates. In addition, its safety data also performs well. Most adverse reactions are mild to moderate, such as fatigue, nausea, etc., and most of them are predictable and manageable.

It is worth mentioning that pemetinib is the first selective FGFR inhibitor approved in China. Its emergence has filled the gap in targeted treatment of cholangiocarcinoma in China. The recommended dose of the drug is 13.5 mg daily for 14 days, followed by 7 days off, forming a 21-day treatment cycle.

Pemetinib has been available in China for some time, and patients who need it can purchase it directly from domestic hospitals. The original version of pemetinib available in China is 4.5mg*14 tablets, and the price is around 30,000 yuan. It is understood that there are original and generic versions of pemetinib abroad. The original version of pemetinib is marketed abroad in a box of 13.5mg*14 tablets and the price is about 72,000 yuan; the generic version of pemetinib is produced by Lucius Pharmaceuticals in Laos, and the specification in a box is 4.5mg*14 tablets and the price is only about 850 yuan. If patients have questions about pemetinib, please consult a regular overseas medical company.

Overall, pemetinib, with its unique targeting and good tolerability, brings new treatment hope to patients with malignant tumors such as cholangiocarcinoma.